- Home
- RLTY vs CCCC Comparison
RLTY vs CCCC Comparison
Compare RLTY & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- CCCC
- Stock Information
- Founded
- RLTY 2022
- CCCC 2015
- Country
- RLTY United States
- CCCC United States
- Employees
- RLTY N/A
- CCCC N/A
- Industry
- RLTY Investment Managers
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- CCCC Health Care
- Exchange
- RLTY Nasdaq
- CCCC Nasdaq
- Market Cap
- RLTY 259.2M
- CCCC 244.9M
- IPO Year
- RLTY N/A
- CCCC 2020
- Fundamental
- Price
- RLTY $15.71
- CCCC $3.01
- Analyst Decision
- RLTY
- CCCC Buy
- Analyst Count
- RLTY 0
- CCCC 5
- Target Price
- RLTY N/A
- CCCC $11.60
- AVG Volume (30 Days)
- RLTY 86.7K
- CCCC 1.8M
- Earning Date
- RLTY 01-01-0001
- CCCC 03-04-2025
- Dividend Yield
- RLTY 9.35%
- CCCC N/A
- EPS Growth
- RLTY N/A
- CCCC N/A
- EPS
- RLTY N/A
- CCCC N/A
- Revenue
- RLTY N/A
- CCCC $33,668,000.00
- Revenue This Year
- RLTY N/A
- CCCC $75.59
- Revenue Next Year
- RLTY N/A
- CCCC N/A
- P/E Ratio
- RLTY N/A
- CCCC N/A
- Revenue Growth
- RLTY N/A
- CCCC 65.45
- 52 Week Low
- RLTY $11.38
- CCCC $2.79
- 52 Week High
- RLTY $14.60
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- RLTY 58.43
- CCCC 33.55
- Support Level
- RLTY $15.35
- CCCC $2.79
- Resistance Level
- RLTY $15.67
- CCCC $3.38
- Average True Range (ATR)
- RLTY 0.24
- CCCC 0.20
- MACD
- RLTY -0.01
- CCCC -0.03
- Stochastic Oscillator
- RLTY 81.36
- CCCC 23.66
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.